Showing 2921-2930 of 5685 results for "".
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a
- Bausch + Lomb Announces Licensing Agreement With Tangible Science for Use of Hydra-Peg Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-announces-licensing-agreement-with-tangible-science-for-use-of-hydra-peg-custom-contact-lens-coating/2480063/Bausch + Lomb announced that it has entered into a worldwide licensing agreement with Tangible Science, allowing Bausch + Lomb to offer the Tangible Hydra-PEG advanced contact lens coating technology for use with several of its Boston gas permeable (GP) materials and scleral lenses. Terms
- Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Planhttps://modernod.com/news/kala-pharmaceuticals-announces-update-to-kpi-121-0-25-development-plan/2480081/Kala Pharmaceuticals provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease.
- SynergEyes and Brien Holden Vision Institute Join Forces for Specialty Contact Lens Developmenthttps://modernod.com/news/synergeyes-and-brien-holden-vision-institute-join-forces-for-specialty-contact-lens-development/2480098/SynergEyes announced a new partnership with the Brien Holden Vision Institute, a translational vision correction center that delivers advanced, customized vision correction for myopes and presbyopes. The exclusive worldwide licensing agreement will enable the manufacturing of design technologies
- HelpMeSee Eye Surgery Simulator Demonstrations Scheduled for the 2018 World Ophthalmology Conference in Barcelonahttps://modernod.com/news/helpmesee-eye-surgery-simulator-demonstrations-scheduled-for-the-2018-world-ophthalmology-conference-in-barcelona/2480099/HelpMeSee is presenting their Eye Surgery Simulator and companion eBook for teaching manual small incision cataract surgery (MSICS) at the International Council of Ophthalmology’s (ICO) 2018 World Ophthalmology Conference (WOC) in Barcelona, Spain. WOC attendees interested in scheduling dem
- CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa Drug Formulationshttps://modernod.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally proce
- EyeSouth Announces Strategic Partnership with South Georgia/North Florida Eye Partnershttps://modernod.com/news/eyesouth-announces-strategic-partnership-with-south-georgia-north-florida-eye-partners/2480107/EyeSouth Partners has completed a strategic partnership with South Georgia/North Florida Eye Partners, and Cataract and Laser Surgery Center of South Georgia, expanding its presence into the South Georgia and North Florida regions. EyeSouth is an eye care-focused physician services organization f
- Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticalshttps://modernod.com/news/nicox-announces-research-collaboration-on-novel-ophthalmic-therapeutics-with-ironwood-pharmaceuticals/2480117/Nicox SA announced its entry into a research collaboration with Ironwood Pharmaceuticals focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new
- BioTime Announces $1.9 Million Grant for Continued Development of OpRegen for Dry-AMDhttps://modernod.com/news/biotime-announces-1-9-million-grant-for-continued-development-of-opregen-for-dry-amd/2480136/BioTime has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (IIA). The grant provides funding for the continued development of OpRegen, and to date the IIA has provided annual grants totaling over $13 mil
- First Series C-Round Closing for Medical Device Company Implandata Ophthalmic Productshttps://modernod.com/news/first-series-c-round-closing-for-medical-device-company-implandata-ophthalmic-products/2480150/Ophthalmic medical device company Implandata Ophthalmic Products announced that the company accomplished a first closing of its Series C funding round. The company was able to raise a “mid-single digit million Euro” amount from a strategic and several institutional and private investo